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Abstract
Background: Hepatitis B virus (HBV) transmission through blood transfusion is reduced by screening for hepatitis B
surface antigen (HBsAg). However this method cannot detect the presence of occult hepatitis B virus infection. This
study sought to determine the prevalence of occult hepatitis B virus infection among blood donors in Ile-Ife,
Nigeria. For the first time in Nigeria we employed an automated real-time PCR- method to investigate the
prevalence of occult HBV in blood donors.
Methods: Blood donors screened with HBsAg immunochromatographic rapid test kits at the blood transfusion units
of two hospitals and found to be negative were recruited into the study. Questionnaires to elicit risk factors for HBV
infection were administered and then 10 ml of blood was collected from each donor. Plasma samples obtained from
these HBsAg negative blood donors were screened again for HBsAg using an enzyme-linked immunosorbent assay
(ELISA) method, and those found negative were screened for the presence of total antibody to the HBV core antigen
(anti-HBc) using ELISA method. Those positive to anti-HBc were then tested for HBV DNA, using an automated real-
time PCR method.
Results: Five hundred and seven blood donors found HBsAg negative by immunochromatographic rapid test kits at
both blood transfusion units, were tested for HBsAg using ELISA and 5 (1 %) were HBsAg positive. The 502 found
negative were tested for anti-HBc and 354 (70.5 %) were found positive implying previous exposure to HBV and 19
(5.4 %) of the 354 anti-HBc positive had HBV DNA signifying occult HBV infection. No risk factors were found to be
associated with the presence of HBV DNA among those who tested positive.
Conclusion: Occult HBV infection exists in blood donors in Ile-Ife, Nigeria and the use of HBsAg alone for screening
prospective donors will not eliminate the risk of HBV transmission in blood transfusion or stem cell transplantation.
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Background
Hepatitis B virus (HBV) infection is a global, public
health issue [1–3] of immense importance. It occurs
worldwide and up to two billion people, approximately
30 % of the world’s population, have been infected glo-
bally [2]. Of this, 300–400 million people are chronically
infected, approximating to about 5 % of the world’s
population at risk of developing the complications of
chronic HBV infection [1–5]. Deaths resulting from
HBV yearly, stand at about 500,000 to 1.2 million world-
wide. Most of these are due to sequelae of chronic HBV
infection such as cirrhosis, liver failure and hepatocellu-
lar carcinoma (HCC) [2–5].
Blood transfusion could be an important route for the
transmission of infection especially when donated blood
is not screened for HBV infection [6]. Screening of do-
nated blood for Hepatitis B surface Antigen (HBsAg)
was introduced in the 1970s [7–10]. This greatly reduced
HBV transmission due to blood transfusions [9, 11] as
blood found to be HBsAg positive was not transfused.
In many developing countries including Nigeria, screen-
ing of blood donors or blood donated, for HBsAg alone, is
still the only practice on which the prevention of HBV
transmission during blood transfusion is based [12].
Numerous scientific papers have highlighted the pres-
ence of HBV infection in some individuals negative for
HBsAg but having detectable HBV DNA in the liver or
blood and some of these publications have documented
HBV transmission resulting from transfusion of blood
tested and found to be HBsAg negative [9, 13–15].
Occult HBV infection (OBI) has been the subject of
numerous publications focusing on different aspects of
and issues relating to OBI [10, 16–51]. It is a term that
has been chosen by experts [33] to denote HBV infec-
tions in which HBsAg cannot be detected and the pres-
ence of infection is only established by amplifying and
detecting HBV DNA [18–22, 28, 33, 34, 46].
One significant importance of OBI is the risk of trans-
mission of HBV from individuals with OBI to recipients.
This could occur if blood or blood components, stem
cells or solid organs are transfused or transplanted
following negative HBsAg results in donors with OBI.
Such infections could manifest overtly becoming HBsAg
positive with possibly fatal consequences, the risk rising with
immune suppressed recipients [14–16, 18, 25, 33, 46, 52, 53].
In Nigeria, which is highly endemic for HBV infection
[54–57], current blood banking practices do not include
procedures that would identify OBI and prevent transfu-
sion of blood or blood products from apparently healthy
donors with OBI to recipients [58].
As the prevalence of OBI tends to be higher where the
prevalence of overt HBV infection is high [27] there may
be a relatively high prevalence of OBI in Nigeria. All of
these translating to an increasing number of patients who
may be at risk of HBV infection from occult donors.
Nevertheless there is limited data on the prevalence of
OBI in blood donors in this country as only HBsAg
screening is still relied upon [12, 58].
Against this background, we sought to investigate the
prevalence of occult HBV in this region, to enable us
make evidence-based recommendations for effective
HBV screening to prevent HBV transmission from do-
nors with OBI to recipients during blood transfusion.
Methods
Ethical issues
Approval was sought and obtained from the Ethics and
Research Committee of Obafemi Awolowo University
Teaching Hospitals Complex (OAUTHC) Ile-Ife with
reference number IRB/IEC/0004553 and the Ethics and
Research Committee of Seventh Day Adventist Hospital
(SDAH), Ile-Ife. Prospective subjects were informed
about the study and written consent was obtained from
those who agreed to participate. The study was a pro-
spective, cross-sectional study.
Selection of study population
Apparently healthy blood donors who had been screened
and found eligible by the respective blood banks for
donation were recruited over a period of six and a half
months, from June 2013 to January 2014. Subjects who
had hepatitis B vaccination in the previous one month
were excluded.
Sociodemographic information
With the aid of a structured questionnaire, relevant
sociodemographic information was obtained from blood
donors. This included age, sex, number of lifetime sexual
partners, presence of tatoos/scarification marks, history
of alcohol use, smoking, sharing of sharps and hepatitis
B vaccination. The questionnaires were self-administered
by subjects or any subjects who needed help in filling
the questionnaires were assisted by trained volunteers
who were medical doctors, medical laboratory scientists,
medical laboratory science students, and laboratory
technologists.
Collection of specimens
Ten milliliters (mls) of venous blood was collected from
each consecutive consenting, eligible, previously screened,
apparently healthy blood donor, donating to the blood
banks at OAUTHC and SDAH in Ile-Ife. The blood was
collected aseptically into a specimen bottle containing
potassium ethylene diamine tetra acetate (K+EDTA)
anticoagulant. All samples were centrifuged at room
temperature at 3500 rpm for 10 min within 24 h of collec-
tion. The plasma was then separated and stored at −70 °C
until analysed.
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Serological analysis
The serological studies were done at the department of
Medical Microbiology and Parasitology, OAUTHC.
HBsAg was tested for in all specimens using commer-
cially available Monolisa™ HBsAg ULTRA ELISA kits
manufactured by BIORAD (3,bd Raymond Poincare,
92430 Marnes-la-Coquette-France) with a lower limit of
detection estimated to be less than 0.13 IU/ml, accord-
ing to the manufacturer’s instructions.
All HBsAg negative plasma samples were then tested
for total anti-HBc using commercially available Mono-
lisa™ Anti-HBc PLUS ELISA kits by BIORAD (3,bd
Raymond Poincare, 92430 Marnes-la-Coquette-France)
according to the manufacturer’s instructions.
HBV DNA studies
Detection and quantification of HBV DNA was done at
the Human Virology Laboratory of the Nigerian Institute
of Medical Research (NIMR) Lagos and all HBsAg nega-
tive, anti-HBc positive plasma samples were tested for
HBV DNA using “COBAS AmpliPrep/COBAS TaqMan
HBV Test version 2.0” kits made by Roche (Roche
Molecular Systems Inc. Branchburg, NJ 08876 USA)
using the “Cobas Ampliprep instrument and COBAS
TaqMan 48 Analyzer” with a limit of detection of less
than 20 IU/ml for HBV DNA. All procedures were per-
formed according to manufacturer’s instructions.
Initial daily maintenance and priming were performed
and specimens and controls were brought to room
temperature. Reagent cassettes and disposables were
then loaded onto the COBAS AmpliPrep Instrument as
per manufacturer’s instructions. Sample racks were pre-
pared, then 650 μl of High Positive control (HPC), Low
Positive Control (LPC), Negative control (NC) and each
specimen was transferred using a micropipette and
DNase-free tips into the appropriate sample input tubes
(S-tubes) The sample racks with S-tubes and K-tubes
were then loaded onto the appropriate rack position on
the COBAS AmpliPrep Instrument.
The COBAS AmpliPrep Instrument was then
started using the AMPLILINK software and auto-
mated specimen processing was done. Each set of
processed specimens in K-tubes, on K- carriers were
then manually transferred to the COBAS TaqMan 48
Analyzer using the K- carrier transporter and the
COBAS TaqMan 48 Analyzer run was then started
for automated real-time PCR amplification and detec-
tion and quantification. At the end of each run the
results were printed out. Positive (HPC and LPC) and
negative controls were included in each run.
Data analysis and statistical techniques
Descriptive statistics were calculated and reported for
sociodemographic characteristics. Percentages were used
to describe frequency analyses of categorical variables.
Chi-squared test was used to compare categorical vari-
ables. A P value < 0.05 was considered to indicate statis-
tical significance. Data processing and statistical analyses
were performed using Epi Info 7 Software by CDC.
Results
Hepatitis B surface antigen testing in donors
Five hundred and seven blood donors tested at both
OAUTHC and SDAH blood banks for HBsAg using
immunochromatographic rapid test kits and found nega-
tive were tested for HBsAg using ELISA and five of them
were found to be HBsAg positive as presented in Table 1.
Assessment of HBsAg negative donors for anti-HBc
The 502 donors found to be HBsAg negative using
ELISA tests were tested for anti-HBc also using ELISA.
Three hundred and fifty four (71 %) were positive giving
an anti-HBc prevalence of 71 % among blood donors.
Real time PCR assays for HBV DNA
Out of the 354 HBsAg negative, anti-HBc positive
subjects whose specimens were tested, HBV DNA was
detected in 19 (5.4 %) as shown in Table 2. The viral
load for those with OBI ranged from 68 to < 20 IU/ml.
Summary of laboratory tests and results
See Fig. 1 below.
Sociodemographic characteristics of subjects with occult
HBV
Nineteen subjects were found to have occult HBV infec-
tion. All (100 %) of them were males and 17 (89.5 %) of
them were less than 35 years (Table 3). There was no
significant association between occult HBV infection
and any of the variables tested as seen in Table 3.
Discussion
In this study we found in HBsAg negative blood do-
nors an anti-HBc prevalence of 70.5 %. This means
over 70 % of our adult population have been infected
with HBV at some point in their lives. This has previ-
ously been reported by others [59] including Kiire
who in 1996 [60] reported that 72.5 % of Nigerians
show evidence of exposure to HBV infection. This
Table 1 HBsAg Screening by ELISA
Blood Bank OAUTHC SDAH Total
Number Screened 405a 102a 507
Number Positive 4 1 5
aPreviously screened and found HBsAg negative by the
immunochromatographic rapid test kits
HBsAg Hepatitis B surface antigen, OAUTHC Obafemi Awolowo University
Teaching Hospitals Complex, SDAH Seventh Day Adventist Hospital
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means that the burden of HBV infection has not
changed significantly over the last 18 years especially
in adults. This is not surprising as they were born be-
fore 2004 when hepatitis B vaccine actually became
widely available as part of the universal immunization
schedule for infants in Nigeria [61]. Other workers
such as Japhet et al. [62] found a prevalence of 5.4 %
for IgM anti-HBc only positive blood donors but did
not look for total anti-HBc. Salawu et al. [63] also
found about 4.4 % of anti-HBc in HBsAg negative do-
nors but in that study rapid test kits were used which
may be less sensitive than the ELISA used in this
study.
This study found an OBI prevalence of 5.4 % among
anti-HBc positive blood donors in Ile-Ife. This means
that after HBsAg screening about 1 in 20 to 1 in 25
blood donations still have HBV DNA. Therefore the risk
of transfusing blood from donors with OBI is about 1 in
20 donations. Published data on OBI in blood donors in
Nigeria is sparse. Nna et al. [64] found a prevalence of
8 % in Abakaliki, South-Eastern Nigeria among 100 do-
nors, Opaleye et al. [65] found a very high prevalence of
36 % among 429 donors while Oluyinka et al. [66] found
a prevalence of 17 % in Southwestern Nigeria among
429 donors. These prevalence values are all higher than
that found in this study. In all three, the method of HBV
DNA detection was nested PCR. Nested PCR has the
significant drawback of being prone to contamination and
false positives especially during the sample transfer step
preceding the second round of amplification [67–69] and
so that may explain the much higher values. The problem
of contamination and false positives in nucleic acid ampli-
fication assays is eliminated in automated real time PCR
assays [70] such as the one we used in this study. However
there may be differences in the prevalence of OBI
among blood donors from one part of the country to
another, reflecting differences in the prevalence of
overt HBV infection which exist from one part of the
country to the other [54–57].
Other studies on OBI in Nigeria have been in other
subject populations such as Ola et al. [71] who found
OBI in 2 of 28 chronic hepatitis patients in Ibadan,
Opaleye et al. [72] also in Nigeria found a prevalence
of 11.2 % of OBI in HIV positive patients using
archived specimens from Ikole Ekiti, however this
subjects were not likely to qualify as blood donors
and as such no risk of their blood being transfused.
Table 2 Quantitative HBV DNA results for HBsAg negative, anti-
HBc positive subjects with occult HBV
Viral Load Number of Subjects HBsAg Anti-HBc
<20 IU/ml 16 Negative Positive
21 IU/ml 1 Negative Positive
64 IU/ml 1 Negative Positive
68 IU/ml 1 Negative Positive
HBsAg Hepatitis B surface antigen, Anti-HBc antibody to hepatitis B core
antigen, IU/ml international units per milliliter
Fig. 1 Summary of Results. Figure one summarizes the laboratory tests done and the results seen in form of a flow chart. There were 507
subjects and their plasma specimens were screened for HBsAg using ELISA and five were positive. The remaining 502 were then screened for
anti-HBc also using ELISA and 354 were found to be positive. The 354 anti-HBc samples were then screened for HBV DNA using real time PCR.
HBV DNA was found in 19. (HBV – Hepatitis B virus, HBsAg –Hepatitis B surface Antigen Anti-HBc – antibody to hepatitis B core antigen, ELISA –
Enzyme linked immunosorbent assay, PCR – Polymerase chain reaction)
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The prevalence in this study was higher than the 1.7 %
found in Ghana by Zahn et al. [73] but this may be be-
cause the HBV DNA was tested for in all blood donors
and not just those that were anti- HBc positive as was
done in this study. HBsAg positive individuals who are
anti-HBc positive have been found to be more likely to
have OBI than those without anti-HBc.
In Brazil, Silva et al. found 3.3 % but used a PCR assay
with a LLOD of about 200 IU/ml [23], which is less sen-
sitive than the real-time PCR assay used in this study.
This could have resulted in a lower detection of OBI.
The prevalence found in this study is much higher
than what has been found in the US and some other
western countries where only 0.1–2.4 % of HBsAg nega-
tive, anti-HBc positive blood donors were found to have
HBV DNA [46, 74]. This is not surprising because only
about 5 % of the population have come in contact with
HBV in those regions unlike in Nigeria where over 70 %
of the population have at some time in their lives been
exposed to or infected with HBV [59, 60].
Manzini et al. in Italy [29] found 4.86 % among HBsAg
negative, anti-HBc positive blood donors which is similar
to what we found.
This prevalence is much smaller than the 38 % that was
reported by Yotsuyanagi et al. in Japan [13] but the sample
size was just 50 blood donors which is small compared to
this study. This may also be the reason why Jafarzahdeh et
al. found a 28.56 % prevalence in Iran [31] as they only
assayed 14 HBsAg negative, anti-HBc positive samples for
HBV DNA and found in four samples.
This study did not find any significant association be-
tween occult HBV and the variables tested such as age,
sex, alcohol use, smoking, sharing of sharps scarification
marks/tattoos and number of lifetime sexual partners.
This is most likely because of the small number (19) of
individuals in which we detected HBV DNA. This num-
ber was probably too small for reliable statistical ana-
lysis. However all those with OBI in this study were
found to be males, mostly less than 36 years.
Of note is that in this study HBsAg was detected
by ELISA in five (1 %) blood donors who had previ-
ously been screened with rapid test kits, declared
HBsAg negative and cleared for donation. In at least
two of these blood donors HBV DNA was demon-
strated by real-time PCR. This shows that the rapid
test kits being used for HBsAg screening in the blood
banks where the subjects were recruited are not ad-
equate for screening in blood transfusion services and
would allow transfusion of HBsAg positive blood in 1
out of every 100 blood donations.
Table 3 Sociodemographic characteristics of anti-HBc positive subjects with/without occult HBV infection
Variables HBV DNA Tests of Statistical Significance
positive(%) negative(%) Χ2 df p

















































P.S For the last three characteristics/variables no responses were available for five of those with occult HBV infection
HBV Hepatitis B virus
Anti-HBc antibody to hepatitis B core antigen, X2 chi square, df degree of freedom, p p-value
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The inadequacy in sensitivity and variation in perform-
ance between different locations of some rapid test kits
used in resource poor settings for HBsAg screening has
been shown by Bjoerkvoll et al. [75]. In their cross-sectional
epidemiological study they compared the accuracy of rapid
test immunochromatographic kits in the detection of
HBsAg, anti-HBc and anti-HCV against ELISA, in two
populations of 1200 potential blood donors in rural
Cambodia and Vietnam. For HBsAg specifically, they found
the rapid test kits to be high in specificity (99.8–99.9 %) but
lower in sensitivity (86.5 %). They also found a difference in
its sensitivity between both countries. In Cambodia the
sensitivity was 93.5 % and in Vietnam 81.8 %.
Anti-HBs prevalence has been studied in Nigeria. Salawu
et. al [63] in a study in Ile-Ife among 457 blood donors
negative for hepatitis B surface antigen(HBsAg) found a
prevalence rate of 12.7 %, Japhet et. al [62] found a rate of
15.2 % among 92 donors also studied in Ile-Ife while
Oluyinka et. al [66] found 35 % of those with OBI had anti-
HBs. However we did not investigate the prevalence of
anti-HBs among blood donors with or without OBI in our
study because we did not have enough funds to do that.
Conclusion
Hepatitis B virus infection is still endemic in Nigeria with
a large percentage of the population showing evidence of
prior exposure to HBV in this environment evidently from
routes other than blood transfusion. There is a relatively
high burden of occult HBV infection in our environment
and the use of HBsAg alone for screening either in blood
transfusion or transplantation services does not eliminate
the risk of HBV transmission.
Recommendations
We recommend that assays including rapid test kits used
for HBsAg screening should be validated before routine
use locally comparing their performance with at least 3rd
generation ELISA. Only ELISA assays or rapid test kits
with comparable performance with regard to sensitivity
or specificity should be used for HBsAg screening in
blood transfusion.
Nucleic acid tests (NATs) should be introduced for
routine screening of donors in blood transfusion and
mandatorily for screening of donors and recipients in
transplantation services. Individual donor (sample) test-
ing using a NAT is more sensitive than testing in pools
and so is preferred for this purpose [76–79].
Limitations
Other HBsAg negative and anti-HBc negative speci-
mens could not be tested by real time PCR because
of the high costs involved. We also were not able to
test for anti-HBs in the specimens of subjects with
OBI because our funds were limited.
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